共 285 条
[1]
Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[2]
Miller KD(2019)The emerging treatment landscape of targeted therapy in non-small-cell lung cancer Signal Transduct Target Ther 4 61-454
[3]
Fuchs HE(2018)The biology and management of non-small cell lung cancer Nature 553 446-529
[4]
Jemal A(2016)Antiangiogenic therapy in oncology: current status and future directions Lancet 388 518-426
[5]
Yuan M(2017)Tumor angiogenesis and vascular normalization: alternative therapeutic targets Angiogenesis 20 409-523
[6]
Huang LL(2015)Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Transl Lung Cancer Res 4 515-313
[7]
Chen JH(2020)The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future Clin Lung Cancer 21 308-673
[8]
Wu J(2014)Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 665-1669
[9]
Xu Q(2019)Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 20 1655-635
[10]
Herbst RS(2019)Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Lancet Oncol 20 625-724